360 related articles for article (PubMed ID: 2535688)
21. Effect of a long-acting somatostatin analogue (SMS 201-995) on a growth hormone and thyroid stimulating hormone-producing pituitary tumor.
Hirasawa R; Hashimoto K; Makino S; Suemaru S; Takao T; Ota Z; Hoshida Y; Yoshino T; Akagi T
Acta Med Okayama; 1991 Apr; 45(2):107-15. PubMed ID: 1867112
[TBL] [Abstract][Full Text] [Related]
22. Response of a GH- and TSH-secreting pituitary adenoma to a somatostatin analogue (SMS 201-995): evidence that GH and TSH coexist in the same cell and secretory granules.
Malarkey WB; Kovacs K; O'Dorisio TM
Neuroendocrinology; 1989 Mar; 49(3):267-74. PubMed ID: 2716953
[TBL] [Abstract][Full Text] [Related]
23. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
24. Clinical use of the somatostatin analog SMS 201-995 in endocrinology.
Cozzi R; Liuzzi A; Dallabonzana D; Oppizzi G; Orlandi P; De Palo C; Petroncini MM; Piolini M; Chiodini PG
J Endocrinol Invest; 1988 Nov; 11(10):737-40. PubMed ID: 2852695
[No Abstract] [Full Text] [Related]
25. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.
George SR; Kovacs K; Asa SL; Horvath E; Cross EG; Burrow GN
Clin Endocrinol (Oxf); 1987 Apr; 26(4):395-405. PubMed ID: 2888549
[TBL] [Abstract][Full Text] [Related]
26. [Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors].
Chanson P; Timsit J; Harris AG
Presse Med; 1993 Dec; 22(40):2009-16. PubMed ID: 7907419
[TBL] [Abstract][Full Text] [Related]
27. The use of somatostatin and its analogs in the treatment of surgical disorders.
Mulvihill S; Pappas TN; Passaro E; Debas HT
Surgery; 1986 Sep; 100(3):467-76. PubMed ID: 2874618
[TBL] [Abstract][Full Text] [Related]
28. A comparison among the effectiveness of growth hormone suppression in active acromegaly of bromocriptine and long acting somatostatin analogue (SMS 201-995).
Popović V; Nesović M; Mićić D; Kendereski A; Djordjević P; Manojlović D; Mićić J
Exp Clin Endocrinol; 1990 Apr; 95(2):251-7. PubMed ID: 1973122
[TBL] [Abstract][Full Text] [Related]
29. Effect of long-term treatment with somatostatin analogue (SMS 201-995) on pituitary tumor shrinkage in acromegaly--report of two cases.
Mukada K; Uozumi T; Takechi A; Arita K; Yano T; Hirohata T; Onda J; Ohta M
Neurol Med Chir (Tokyo); 1992 Apr; 32(4):215-9. PubMed ID: 1378566
[TBL] [Abstract][Full Text] [Related]
30. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment.
Polak M; Bertherat J; Li JY; Kujas M; Le Dafniet M; Weizani H; Van Effenterre R; Epelbaum J; Turpin G
Acta Endocrinol (Copenh); 1991 Apr; 124(4):479-86. PubMed ID: 1851593
[TBL] [Abstract][Full Text] [Related]
31. Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor: case report.
Altstadt TJ; Azzarelli B; Bevering C; Edmondson J; Nelson PB
Neurosurgery; 2002 Jun; 50(6):1356-9; discussion 1360. PubMed ID: 12015856
[TBL] [Abstract][Full Text] [Related]
32. Endocrine applications of the somatostatin analogue octreotide (Sandostatin).
Ezzat S; Melmed S
Metabolism; 1992 Sep; 41(9 Suppl 2):34-8. PubMed ID: 1518431
[No Abstract] [Full Text] [Related]
33. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
[TBL] [Abstract][Full Text] [Related]
34. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a.
Lamberts SW; Reubi JC; Uiterlinden P; Zuiderwijk J; van den Werff P; van Hal P
Endocrinology; 1986 Jun; 118(6):2188-94. PubMed ID: 2870915
[TBL] [Abstract][Full Text] [Related]
35. Effect of octapeptide somatostatin analogue (SMS 201-995) on plasma 7B2 (a neuroendocrine polypeptide) levels in patients with acromegaly.
Natori S; Iguchi H; Ohashi M; Nakao R; Bloom SR; Nawata H
Clin Endocrinol (Oxf); 1990 Jan; 32(1):49-55. PubMed ID: 2331811
[TBL] [Abstract][Full Text] [Related]
36. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
37. Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
Lee EJ; Kim KR; Lim SK; Lee HC; Kim DI; Kim SH; Huh KB
Eur J Endocrinol; 1994 Jul; 131(1):109-12. PubMed ID: 8038902
[TBL] [Abstract][Full Text] [Related]
38. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.
Roti E; Minelli R; Gardini E; Salvi M; Bianconi L; Balducci L; Manfredi A; Braverman LE
J Endocrinol Invest; 1990 Jan; 13(1):69-72. PubMed ID: 2319110
[TBL] [Abstract][Full Text] [Related]
39. Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma.
Koelz A; Kraenzlin M; Gyr K; Meier V; Bloom SR; Heitz P; Stalder H
Gastroenterology; 1987 Feb; 92(2):527-31. PubMed ID: 2878857
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.
Anderson JV; Bloom SR
Scand J Gastroenterol Suppl; 1986; 119():115-28. PubMed ID: 2876495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
